Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Finished Goods: 2024-2025

  • ARS Pharmaceuticals' Finished Goods was N/A to $7.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.3 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2024, which is N/A change from last year.
  • ARS Pharmaceuticals' Finished Goods amounted to $7.3 million in Q1 2025, which was up 39.49% from $5.2 million recorded in Q4 2024.
  • In the past 5 years, ARS Pharmaceuticals' Finished Goods registered a high of $7.3 million during Q1 2025, and its lowest value of $5.2 million during Q4 2024.
  • Its 2-year average for Finished Goods is $6.2 million, with a median of $6.2 million in 2024.